All In Biotech

Drug Trial Radar · NCT06509334

Trial of JYB1904 in Chronic Spontaneous Urticaria.

A Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Adult Patients with Chronic Spontaneous Urticaria Inadequately Controlled by H1 Antihistamines

Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Aug 4, 2024

Primary completion

Jul 15, 2026

Study completion Jul 15, 2026

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
First posted
Jul 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase II Trial is Meant to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Patients With Chronic Spontaneous Urticaria.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • JYB1904Drug

    Participants will receive JYB1904 at week0 and receive placebo at week4,8,12

  • JYB1904Drug

    Participants will receive JYB1904 at week0,8 and receive placebo at week4,12

  • OmalizumabDrug

    Participants will receive Omalizumab every 4 weeks for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Urticaria activity score used for 7 consecutive days(UAS7)Time frame: Baseline through 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.